Skip to content
DataLookout
Start free
Menu

BRIGHTNCT07789678

Epidemiological Profile of Patients With IDH-Mutant Diffuse Gliomas Diagnosed From 2021 in Brazil

StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Study title shortened, about 7 wordsv2
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Epidemiological profile of patients with IDH-mutant diffuse gliomas
Timeframe: Baseline

Secondary (12)

Progression-Free Survival (PFS)
Overall Survival (OS)
Objective Response Rate (ORR)
Treatment Patterns and Sequencing
Dose Reduction and Discontinuation Rates
Show 7 moreShow less
Time to Next Intervention (TTNI)
Interval Between Last Surgery and First Systemic Therapy or Radiotherapy
Time From Initial Diagnosis to First Systemic or Radiotherapy Initiation
Prevalence of Seizures at First Systemic Therapy
Karnofsky Performance Status (KPS) Score
Karnofsky Performance Status (KPS) Deterioration
Frequency and Results of Molecular Testing

Arms and interventions

IDH-mutant diffuse glioma cohort

Male or female patients aged 12 years or older histologically confirmed diagnosis of diffuse glioma from 2021 and confirmed IDH mutation identified by IHC or PCR/NGS.

Sites

12 sites in 1 country